Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects
Identifieur interne : 000274 ( PascalFrancis/Checkpoint ); précédent : 000273; suivant : 000275Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects
Auteurs : O. Ukkola [Finlande] ; Y. A. Kes Niemi [Finlande]Source :
- European journal of clinical nutrition [ 0954-3007 ] ; 2007.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Association, Homme, Nutrition.
English descriptors
- KwdEn :
Abstract
Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:07-0426249Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</title><author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1><s2>Oulu</s2><s3>FIN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Finlande</country><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author><author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1><s2>Oulu</s2><s3>FIN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Finlande</country><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0426249</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0426249 INIST</idno><idno type="RBID">Pascal:07-0426249</idno><idno type="wicri:Area/PascalFrancis/Corpus">000330</idno><idno type="wicri:Area/PascalFrancis/Curation">000237</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000274</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</title><author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1><s2>Oulu</s2><s3>FIN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Finlande</country><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author><author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1><s2>Oulu</s2><s3>FIN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Finlande</country><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">European journal of clinical nutrition</title><title level="j" type="abbreviated">Eur. j. clin. nutr.</title><idno type="ISSN">0954-3007</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of clinical nutrition</title><title level="j" type="abbreviated">Eur. j. clin. nutr.</title><idno type="ISSN">0954-3007</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Association</term><term>Human</term><term>Middle age</term><term>Nutrition</term><term>Polymorphism</term><term>Risk</term><term>Risk factor</term><term>Type 2 diabetes</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Diabète type 2</term><term>Polymorphisme</term><term>Association</term><term>Facteur risque</term><term>Risque</term><term>Age mûr</term><term>Homme</term><term>Nutrition</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Association</term><term>Homme</term><term>Nutrition</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0954-3007</s0></fA01><fA03 i2="1"><s0>Eur. j. clin. nutr.</s0></fA03><fA05><s2>61</s2></fA05><fA06><s2>9</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</s1></fA08><fA11 i1="01" i2="1"><s1>UKKOLA (O.)</s1></fA11><fA11 i1="02" i2="1"><s1>KESÄNIEMI (Y. A.)</s1></fA11><fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1><s2>Oulu</s2><s3>FIN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA20><s1>1102-1105</s1></fA20><fA21><s1>2007</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18249</s2><s5>354000149692660090</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1/2 p.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0426249</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>European journal of clinical nutrition</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.</s0></fC01><fC02 i1="01" i2="X"><s0>002B22</s0></fC02><fC02 i1="02" i2="X"><s0>002B21E01A</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Diabète type 2</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Type 2 diabetes</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Polymorphisme</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Polymorphism</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Polimorfismo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Association</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Association</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Asociación</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Risque</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Risk</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Riesgo</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Age mûr</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Middle age</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Edad media</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Nutrition</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Nutrition</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Nutrición</s0><s5>11</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Endocrinopathie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Endocrinopathy</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Endocrinopatía</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Métabolisme pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Metabolic diseases</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Metabolismo patología</s0><s5>38</s5></fC07><fN21><s1>281</s1></fN21></pA></standard></inist><affiliations><list><country><li>Finlande</li></country></list><tree><country name="Finlande"><noRegion><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name></noRegion><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000274 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000274 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:07-0426249
|texte= Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects
}}
| This area was generated with Dilib version V0.6.21. |  |